
#wetware: conservación, tecnología, economía de genes. reservas estratégicas de ADN. mercados de información. economía post-genómica, post-petrolera
California, Ecuador
Joined May 2012
- Tweets14.4K
- Following156
- Followers395
- Likes917
biodiversidad retweeted
digital DNA
teapawt.net/_biodiversa/status/162…
Monsanto Canada v. Schmeiser
teapawt.net/_biodiversa/status/161…
bioeconomy
teapawt.net/_biodiversa/status/168…
agriculture
teapawt.net/_biodiversa/status/169…
wetware
teapawt.net/_biodiversa/status/169…
anything
teapawt.net/_biodiversa/status/153…
genetic resources
teapawt.net/_biodiversa/status/150…
#DSI
NEW: New York Times considers legal action against OpenAI as copyright tensions swirl
npr.org/2023/08/16/119420256…
biodiversidad retweeted
Monsanto Canada Inc. v. Schmeiser
decisions.scc-csc.ca/scc-csc…
the new oil
teapawt.net/_biodiversa/status/160…
patents, risk
teapawt.net/_biodiversa/status/160…
digital sequence information
#DSI
what is the legal definition of "genetic resource" and "digital sequence information"?
what does "as applicable" mean?
who defines fairness and equitability?
patents, risk?
teapawt.net/_biodiversa/status/160…
@OscarALizarazo
@KlausRiede
@synbiomaria
@aysirakaya
@Basecamp_Res
thanks!
biodiversidad retweeted
Aichi Target 5: habitat loss, not achieved
teapawt.net/_biodiversa/status/139…
royalties as low as 0.01%, gene patents
teapawt.net/_biodiversa/status/150…
bioeconomy, US$0.5-1.4 trillion
teapawt.net/LBNLBioSci/status/1359…
industria del ADN
teapawt.net/_biodiversa/status/149…
#DSI #Nagoya
A new #BioScience Viewpoint offers community-generated recommendations for enabling effective access and benefit sharing of digital sequence information.#aibs #journal academic.oup.com/bioscience/…
biodiversidad retweeted
Yes
Biotech still runs on who owns the patent and who approves the drug.
That was my takeaway from @alexkesin's session at DataDrivenPharma West last week.
Alex wrote one of the most widely shared analyses of China's biotech rise this year, and it has become a reference point in the policy debate. He also co-hosts @approvedfm with [@MatthewPech], a podcast on how drugs get discovered, developed and sold. He walked a room of operators through where the value sits now.
Four quick hits:
- 1:3. Doing the work in China costs a half to a third of the US price.
- Rent, don't sell. Beijing's new export controls block the sale of biotech platforms. Licensing, partnerships and contract research stay open.
- 3x. China tripled its university patent conversion rate in two years, to 10.1%.
- 8% to 32%. China's share of the global early-stage pipeline, from 2015 to 2024.
The first hit explains the last five years. China got cheap and fast, and the West bought what it built. Most of those deals were fast-follows on targets Western labs discovered. The West owned the original IP and rented China's speed.
The other three point to the next five.
The export controls dropped the same morning as the session. Read them next to the new five-year plan, which makes biotech and biomanufacturing a national priority through 2030. The strategy looks clear to me. Generate IP faster than the US, keep ownership at home, and let the world license it.
Pipeline share has quadrupled. Patents are moving out of universities and into companies. Nine out of ten still sit unused, so there's plenty of room to grow.
Patents are still the currency. Regulators still set the exchange rate. The FDA turned away a Chinese PD-1 copycat because its trial ran only on Chinese patients. To get paid in the US, you still need FDA approval and a partner who can launch here.
What changes is who holds the paper. When the West generated the IP, licensing meant Western companies owned the value and paid for speed. As more IP is generated and kept in China, the same deal structure sends more value the other way. The West ends up renting the molecule instead of owning it.
This is a gold rush for intellectual property. The question is who can generate novel IP in a specific area, and do it first.
Therapeutics is the beachhead. The US market pays enough for new drugs that the long road through the FDA still earns a return.
In this gold rush, anyone can be a miner. The fastest ones will have the best maps.
And maps only come from data.
#ddpwest26
biodiversidad retweeted
Amazon’s new AI Bio Discovery tool can provide ‘every researcher’ with ‘lab-in-the-loop drug discovery’ – 40+ AI biology models can filter 300,000 novel antibody candidates down to the top results for testing in just weeks | @techradar
techradar.com/pro/amazons-ne…
biodiversidad retweeted
14 (a) Should economic rent be charged for access to genetic resources? What should be the basis for the valuation of such rent?
cbd.int/decision/cop?id=1165…
Ozempic, ~US$14 billion
qz.com/ozempic-weight-loss-d…
digital sequence information
#DSI
Replying to @_biodiversa
Enclosure A
(a) Pharmaceuticals;
(d) Biotechnology;
(f) Information, scientific, technical services related to #DSI on genetic resources including AI (?)
cbd.int/doc/c/8125/22ca/baa2…
IP, risk
teapawt.net/_biodiversa/status/180…
biodiversidad retweeted
The synthetic biology revolution is upon us, and its TRILLIONs of dollars of value to be created. SynBioBeta has their conference again in Oakland May 23-25 I urge you to go or to follow what is happening.
forbes.com/sites/johncumbers…
biodiversidad retweeted
AI + bio: Next Generation Machine Learning
liebertpub.com/doi/10.1089/g…
bioeconomy, >US$1 trillion
teapawt.net/_biodiversa/status/185…
royalties
teapawt.net/_biodiversa/status/160…
sequence Earth
teapawt.net/_biodiversa/status/179…
IP
teapawt.net/_biodiversa/status/183…
digital sequence information
#DSI
Replying to @_biodiversa
AI + bio
teapawt.net/_biodiversa/status/186…
A powerful pairing
mckinsey.com/capabilities/mc…
biodiversidad retweeted
predict lab-of-origin of engineered DNA
nature.com/articles/s41467-0…
country of origin?
countries exercise sovereign rights over genetic resources
teapawt.net/_biodiversa/status/128…
those prized genes can be assembled in a laboratory to churn out anything
teapawt.net/_biodiversa/status/125…
#DSI #Nagoya
drivendata.org/competitions/…
Your goal is to create an algorithm that identifies the most likely lab-of-origin for genetically engineered DNA.
biodiversidad retweeted
Información Genómica Digital
libreriametagenomica.wordpre…
Predict the lab-of-origin of engineered DNA
nature.com/articles/s41467-0…
Digital-to-biological converter
nature.com/articles/nbt.3859
Ecuador, 2020
teapawt.net/_biodiversa/status/132…
WIPO, IP, genes
teapawt.net/_biodiversa/status/135…
#DSI #Nagoya
WIPO, Intellectual Property, Genes
community.abs-sustainabledev…
gene patents
advances.sciencemag.org/cont…
digital DNA, #DSI
sciencemag.org/news/2016/11/…
How big is the #bioeconomy? US$0.5-1.4 trillion
teapawt.net/LBNLBioSci/status/1359…
biodiversidad retweeted
genome privacy
teapawt.net/_biodiversa/status/165…
digital sequence information
#DSI
biodiversidad retweeted
DNA-based watermarks are helpful tools to identify the unauthorized use of genetically modified organisms (GMOs) protected by patents
bmcmolbiol.biomedcentral.com…
Labeling genes and genetically modified organisms with DNA watermarks
biopharminternational.com/vi…
tracking, paying for genes
teapawt.net/_biodiversa/status/150…
#DSI #Nagoya
#COP15
biodiversidad retweeted
How big is the #bioeconomy in money? 0.5 to 1.4 trillion US dollars, Jeff Furman says. #AAASmtg @BUQuestrom
biodiversidad retweeted
12,998 #DSI, 862 species. BASF: 47% of gene patents, universities: 12%. 10 countries registered 98% of all gene patents, 165 countries unrepresented.
science.org/doi/10.1126/scia…
Who Owns the Rights to Wonder Plants?
e360.yale.edu/features/indig…
#Nagoya
"Navigating access and benefit-sharing of plant genetic resources and digital sequence information"
#DSI benefits must be distributed equitably in a way that supports biodiversity conservation & enables research progress & innovation.
9 videos playlist 👉buff.ly/3JhR2J4
biodiversidad retweeted
California Attorney General Rob Bonta sued the genetic testing company formerly known as 23andMe over its handling of a 2023 data breach that exposed nearly 7 million users’ sensitive personal information, including genetic data. news.bloomberglaw.com/privac…
biodiversidad retweeted
Every country holds their rights over plants, animals and genetic resources that are found in its borders. This was agreed upon in #Rio in 1992.🌿
Through #ABS the rights of countries and local communities are respected for a fair use of #geneticresources. 🧬⚖️@UNBiodiversity
The #AcccessAndBenefitSharing 🤝or ABS principle is the third objective of the Convention of Biological Diversity.
Watch @ABSBiotrade's video that simply explains the ABS principle and the #NagoyaProtocol:
youtube.com/watch?v=09zflWUI…
#theABSweALLneed
biodiversidad retweeted
wonder plants, patents
teapawt.net/_biodiversa/status/152…
pharming, how to end medicine shortage
teapawt.net/_biodiversa/status/150…
key messages, #Nagoya
teapawt.net/GermanNagoyaHuB/status…
#DSI
#COP15
#GiveGenesAChance!
In 2023 the EU commission will release a draft of a new regulation for gene-edited crops for debate. Give Genes A Chance (@GGAChance) will be following this process, building a network of young scientists across Europe and giving them a voice.
💚🧬 #synbio
biodiversidad retweeted
royalties as low as 0.01% for use of genetic resources resulting in intellectual property
teapawt.net/_biodiversa/status/150…
47% of gene patents
teapawt.net/_biodiversa/status/150…
next-generation biotechnologies remain vastly unexplored
teapawt.net/_biodiversa/status/150…
#DSI #Nagoya
Sign your name now to voice your support for international polices on digital sequence information that protect #openscience, increase benefit-sharing, and promote research that helps protect and conserve #biodiversity
dsiscientificnetwork.org/ope…
#openDSI
biodiversidad retweeted
Enclosure A
(a) Pharmaceuticals;
(d) Biotechnology;
(f) Information, scientific, technical services related to #DSI on genetic resources including AI (?)
cbd.int/doc/c/8125/22ca/baa2…
IP, risk
teapawt.net/_biodiversa/status/180…
digital sequence information, the new oil
teapawt.net/_biodiversa/status/176…
agriculture, IP, trade, risk
teapawt.net/_biodiversa/status/167…
synthesize anything
teapawt.net/_biodiversa/status/172…
natural products
teapawt.net/_biodiversa/status/179…
#DSI

































